Showing results (511-520 of 533) with videos related to

Sort By:
Pageof 54
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Aging Cell|June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's diseaseStephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Science (New York, N.Y.)|June 29, 2019
A single fast radio burst localized to a massive galaxy at cosmological distanceK W Bannister, A T Deller, C Phillips, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Neurology|January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Brain : a Journal of Neurology|March 17, 2025
Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndromeRobin C M Thomma, Susan K Halstead, Laura C de Koning, et al.
Nature Neuroscience|July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Molecular Psychiatry|March 23, 2019
The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 54